About Armis Biopharma
Armis Biopharma is a private company based in Fort Collins, Colorado. It has reported $21,162,120 raised in eight offerings on Form D since April 2014.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jun 27, 2025 | Jul 10, 2025 | $1,000,000of $3.0M target | 1 | $1.0M | EquityRule 506(b) | Form D ↗ |
| May 15, 2020 | Feb 15, 2022amended Sep 15, 2022 | $7,270,000of $10.0M target | 14 | $519K | Convertible NotesRule 506(b) | Form D/A ↗1 earlier filing |
| Jun 22, 2018 | Sep 25, 2018 | $1,832,300of $10.0M target | 19 | $96,437 | EquityRule 506(b) | Form D ↗ |
| Oct 30, 2017 | Nov 17, 2017 | $125,000of $30.0M target | 1 | $125K | EquityRule 506(b) | Form D ↗ |
| Feb 16, 2017 | Jan 27, 2017amended Nov 17, 2017 | $2,744,835of $14.0M target | 7 | $392K | Equity, OptionsRule 506(b) | Form D/A ↗3 earlier filings |
| Jan 27, 2016 | Mar 10, 2016amended Jun 1, 2016 | $3,255,561of $5.7M target | 16 | $203K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Mar 16, 2015 | Feb 26, 2016 | $1,736,920fully sold | 19 | $91,417 | EquityRule 506(b) | Form D ↗ |
| Feb 7, 2014 | Apr 14, 2014amended Apr 17, 2014 | $3,197,504fully sold | 20 | $159K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Total, eight offerings | $21,162,120 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Armis Biopharma's Form D filed Jul 10, 2025.
Earlier filings also listed Ted Ziemann (executive officer and director, last listed Sep 2022), Ed Neas, Ph.D. (director, last listed Sep 2022), Christopher Ruud (executive officer and director, last listed Sep 2022), William Nelson (director, last listed Sep 2018), Robert Kali (chief financial officer, last listed Sep 2018), Ed Neas (director, last listed Sep 2018), Dennis Templar (executive officer and director, last listed Sep 2018) and Alan Smith (director, last listed Sep 2018).
Sources
- SECArmis Biopharma, Inc. Form D, filed Feb 15, 2022
- SECArmis Biopharma, Inc. Form D/A, filed May 12, 2017
- SECArmis Biopharma, Inc. Form D/A, filed Feb 9, 2017
- SECArmis Biopharma, Inc. Form D, filed Jan 27, 2017
- SECArmis Biopharma, Inc. Form D, filed Mar 10, 2016
- SECArmis Biopharma, Inc. Form D, filed Apr 14, 2014
- SECArmis Biopharma, Inc. filing history